Sangamo Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program, an investigational epigenetic regul ...

Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had ...

Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

NexGenEsis Healthcare is in the business of helping your body heal itself. They are skilled in noninvasive nerve and joint ...

Neuralgia, characterized by acute paroxysmal pain radiating along the course of one or more nerves, is a significant concern ...